Results 251 to 260 of about 273,435 (319)

Gellan Gum Fluid Gel System for Controlled‐Delivery of Cytokine‐Licensed MSC‐EVs to Enhance Corneal Repair in Limbal Stem Cell Deficiency

open access: yesAdvanced Healthcare Materials, EarlyView.
Gellan gum fluid gel (FG) enables controlled ocular delivery of mesenchymal stromal cell (MSC)‐derived extracellular vesicles (EV). Its shear‐thinning, solid‐liquid‐solid rheology ensures prolonged ocular retention. Sustained MSC‐EV release (∼18% in 6 hrs) supports effective EV ocular delivery.
Seyedmohammad Moosavizadeh   +7 more
wiley   +1 more source

POSS‐PEG‐NHS and GSH Cocrosslink DPAV to Prepare Anticalcification Bioprosthetic Scaffold With Enhanced Reendothelization, Anti‐inflammation, and Anti‐ROS

open access: yesAdvanced Healthcare Materials, EarlyView.
POSS‐PEG‐NHS and GSH cocrosslinked DPAV to prepare a multifunctional anticalcification valve substitute. This modification enhances mechanical properties, hemocompatibility, and re‐endothelialization while promoting anti‐inflammatory M2 macrophage infiltration and reducing calcification.
Yuqing Zhang   +10 more
wiley   +1 more source

Nuclear waste radionuclides unveil three decades of anthropogenic carbon in the Canada Basin of the Arctic Ocean. [PDF]

open access: yesNat Commun
Payne A   +7 more
europepmc   +1 more source

Gardiquimod Nanoemulsion Targets Cutaneous Leishmaniasis Lesions Reducing Systemic Toxicity and Parasite Burden

open access: yesAdvanced Healthcare Materials, EarlyView.
Nanoemulsion delivery of a TLR7 agonist enhances safety and promotes colocalization with Leishmania‐infected macrophages in skin lesions, enabling a ∼2‐log reduction in parasite burden. However, tissue‐level constraints and TLR‐driven regulatory feedback generate a mixed immune response that limits complete parasite clearance.
Carmen Palomino‐Cano   +11 more
wiley   +1 more source

From microbial diversity to functional potential using dimensionality reduction. [PDF]

open access: yesFront Microbiol
Chamberlain EJ   +7 more
europepmc   +1 more source

Temporal Immune and Metabolic Shifts Drive the Anti‐Tumor Efficacy of Resiquimod‐Loaded Nanoparticles in Peritoneal Carcinomatosis

open access: yesAdvanced Healthcare Materials, EarlyView.
Peritoneal carcinomatosis is a hard‐to‐treat spread of abdominal cancers that often returns after therapy. Nanoparticles were developed to retain an immune‐boosting drug in the abdomen. When combined with chemotherapy in mice, this approach eliminated tumors in many cases and prevented recurrence, helping the immune system mount a stronger, longer ...
Vanessa Chan   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy